Anandamide Inhibits Vascular Smooth Muscle Migration, Endothelial Adhesion Protein Expression and Monocyte Adhesion of Human Coronary Artery Cells
Open Access
Abstract
Endocannabinoids have been shown to play a complex role in the pathophysiology of a number of cardiovascular disorders. In the present study, the effects of the two major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were investigated in human coronary artery smooth muscle cells (HCASMC) and human coronary artery endothelial cells (HCAEC) with regard to potential atheroprotective and anti-inflammatory effects. In HCASMC, AEA showed an inhibitory effect on platelet-derived growth factor-induced migration, but not proliferation, independent of major cannabinoid-activatable receptors (CB1, CB2, TRPV1), while 2-AG left both responses unaffected. In HCAEC, AEA at concentrations of 6 and 10 µM significantly inhibited the interleukin (IL)-1β- and lipopolysaccharide (LPS)-stimulated expression of vascular cell adhesion molecule-1 (VCAM-1) and LPS-induced intercellular adhesion molecule-1 (ICAM-1), again independently of the abovementioned receptors. Corresponding effects were observed to a lesser extent in the presence of 2-AG, in most cases not significantly. The detection of activated phosphoproteins as well as experiments with inhibitors of corresponding signaling pathways suggest that AEA interferes with IL-1β-induced VCAM-1 expression via inhibition of protein kinase B/Akt and Src kinase activation and attenuates LPS-induced VCAM-1 and ICAM-1 expression via inhibition of signal transducer and activator of transcription 3 (STAT3) phosphorylation. As expected, AEA also led to a significant inhibition of monocyte adhesion to IL-1β- and LPS-stimulated HCAEC, with siRNA experiments confirming the functional role of VCAM-1 and ICAM-1 in this assay. 2-AG showed a comparatively weaker but, in the case of LPS stimulation, still significant inhibition of adhesion. In summary, the results emphasize the potential of AEA as a protective regulator of atherosclerotic and inflammation-related changes in HCASMC and HCAEC and encourage further corresponding preclinical studies with this endocannabinoid.Keywords
Funding Information
- Federal Ministry of Education and Research (BMBF), Germany (03ZZ0933A)
This publication has 76 references indexed in Scilit:
- ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesisJournal of Leukocyte Biology, 2020
- The endocannabinoid system in cardiovascular function: novel insights and clinical implicationsClinical Autonomic Research, 2017
- Anandamide oxidative metabolism-induced endoplasmic reticulum stress and apoptosisApoptosis, 2017
- Anandamide‐induced endoplasmic reticulum stress and apoptosis are mediated by oxidative stress in non‐melanoma skin cancer: Receptor‐independent endocannabinoid signalingMolecular Carcinogenesis, 2015
- Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytesJournal of Orthopaedic Research, 2014
- Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell lineDiabetologia, 2011
- PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3β/GATA-6 signaling pathways in TNF-α-activated human endothelial cellsAtherosclerosis, 2010
- Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5‐HT3 receptor‐mediated responses in Xenopus oocytesSynapse, 2002
- P38 Mitogen Activated Protein Kinase Regulates Endothelial VCAM-1 Expression at the Post-transcriptional LevelBiochemical and Biophysical Research Communications, 1997
- Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing proteinInflammation, 1995